Moxifloxacin Hydrochloride Drug Due Diligence Report 2026

This Moxifloxacin Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

478

Registered trials

132

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Moxifloxacin Hydrochloride can convert its Small molecule drug profile and Bacterial Top II x Bacterial top IV biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Moxifloxacin Hydrochloride (query alias: moxifloxacin)
Modality / target	Small molecule drug; Bacterial Top II x Bacterial top IV; Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors
Highest global status	Approved
Originator	Bayer AG
Active developers	Bayer Yakuhin Ltd., Fresenius Kabi USA LLC, Bayer Pharma AG

The MCP disease footprint includes Complicated intra-abdominal infection, Blepharitis, Conjunctivitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07595042	Phase 2	Not yet recruiting	900	Lower-risk group: Proportion of participants with sustained cure at 52 weeks after randomization
NCT07559149	Phase 2	Completed	32	Corneal Re-epithelialization
ChiCTR2600125828	Not Applicable	Not yet recruiting	74	All-cause mortality? at Month 12

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Phase 3; n=330; evaluation: not stated. Reported fields: Best Spectacle-Corrected Visual Acuity(Mean) = 0.666 logMAR (Standard Deviation, 0.675); -; -

A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of Evobrutinib on the QTc (Corrected QT) Interval in Healthy Adult Participants

Phase 1; n=36; evaluation: not stated. Reported fields: -; -; -

A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of LOXO-292 on the QTc Interval in Healthy Adult Subjects

Phase 1; n=32; evaluation: not stated. Reported fields: Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C(Least Squares Mean) = 3.4 milliseconds (90% Confidence Interval, 0.40 - 6.34); -; Cardiodynamics: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) for Treatments A, B, and C(Least Squares Mean) = 6.4 milliseconds (90% Confidence Interval, 3.38 - 9.43)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Moxifloxacin Hydrochloride addresses Complicated intra-abdominal infection, Blepharitis, Conjunctivitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-05-11	科兴制药与大光制药达成出海合作携手拓展眼科产品海外市场	Approved	Financial terms not disclosed
2025-10-29	红杉中国100%控股拜复乐	Approved	US$302.5M stated total
2021-12-20	Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®	Approved	US$130.0M upfront; US$45.0M milestones; US$175.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Moxifloxacin hapten, moxifloxacin antigen, moxifloxacin antibody and preparation method and application thereof”. The milestone feed surfaced a patent-application signal described as “Preparation method for reducing impurity content in moxifloxacin hydrochloride”. The milestone feed surfaced a patent-application signal described as “Use of moxifloxacin as a senomorphic drug”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO